Filtered By:
Cancer: Liver Cancer
Education: Grants
This page shows you your search results in order of date.
Order by Relevance | Date
Total 86 results found since Jan 2013.
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
EClinicalMedicine. 2023 Aug 30;63:102179. doi: 10.1016/j.eclinm.2023.102179. eCollection 2023 Sep.ABSTRACTBACKGROUND: Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness and safety in other populations, including those with Child-Turcotte-Pugh (CTP) class B cirrhosis, is unclear.METHODS: For this systematic review and meta-analysis, electronic databases, including PubMed, Embase, and Scopus, were searched from 1st May, 2020 till 5th October, 2022; the last date of access was January 31, 2023. Pooled progression-...
Source: Cancer Control - September 8, 2023 Category: Cancer & Oncology Authors: Anand V Kulkarni Harshvardhan Tevethia Karan Kumar Madhumita Premkumar Mark D Muttaiah Atsushi Hiraoka Takeshi Hatanaka Toshifumi Tada Takashi Kumada Satoru Kakizaki Arndt Vogel Richard S Finn Padaki Nagaraja Rao Anjana Pillai Duvvur Nageshwar Reddy Amit Source Type: research
Would a 6-Month Wait Time for Patients With Hepatocellular Carcinoma Improve Organ Allocation in Centers With Active Living Related Liver Transplant Activity?
CONCLUSIONS: This study suggests that implementation of the 6-month wait time for patients with hepatocellular carcinoma before granting exception points may not be necessary for active living related liver transplant programs. Nevertheless, this remains a sound strategy to follow.PMID:36919721 | DOI:10.6002/ect.2022.0369
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - March 15, 2023 Category: Transplant Surgery Authors: Mohammed F Shaheen Abdulrahman Alomar Malek Alrasheed Fisal Aldokhel Abdulazeez Alsaleh Hamdan Alghamdi Wael O'hali Khalid Bin Saad Source Type: research
Distinct phenotypic spectra of hepatocellular carcinoma in liver-specific tumor suppressor-deficient hepatitis B virus transgenic mice
Virology. 2022 Aug 7;574:84-95. doi: 10.1016/j.virol.2022.08.002. Online ahead of print.ABSTRACTThe hepatitis B virus (HBV) transgenic mouse model was used to interrogate the origins of HCC heterogeneity. HBV biosynthesis was used as a marker of liver tumor heterogeneity. Principal component and correlation analysis of HBV and cellular transcript levels demonstrated major differences within and between the gene expression profiles of Apc-deficient, Apc-deficient Pten-deficient, and Pten-deficient HCC. Hence, both oncogenic stimuli and zonal hepatocyte properties determine heterogeneous HCC phenotypes. Additionally, Apc-def...
Source: Cancer Control - August 12, 2022 Category: Cancer & Oncology Authors: Grant Tarnow Rachel Matrenec Claudia E Oropeza Mark Maienschein-Cline Alan McLachlan Source Type: research
Early detection of hepatocellular carcinoma with methylation and fragmentation signatures of circulating tumour DNA: a prospective, multicentre, case-control, observational study
This study was supported by the National Key Research and Development Program of China (grant number 2019YFC1315800).PMID:35837910 | DOI:10.1016/S1470-2045(22)00414-4
Source: Cancer Control - July 15, 2022 Category: Cancer & Oncology Authors: Xinrong Yang Jian Zhou Jia Fan De-Zhen Guo Ao Huang Chengcheng Ma Minjie Xu Wei Li Zhixi Su Source Type: research
